M. Schaafsma

发表

Cytarabine dose for acute myeloid leukemia.

Augustin Ferrant, Bob Löwenberg, Alois Gratwohl, 2011, The New England journal of medicine.

Genomic array as compared to karyotyping in myelodysplastic syndromes in a prospective clinical trial

E. Vellenga, J. Jansen, G. Ossenkoppele, 2017, Genes, chromosomes & cancer.

Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

M. Kersten, D. Hose, H. Goldschmidt, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Final analysis of a randomized study on the value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high risk myelodysplastic syndromes and elderly AML

G. Peters, P. Sonneveld, W. Graveland, 2002 .

First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy

R. Greil, M. Ziepert, W. Stevens, 2012 .

Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial

P. Sonneveld, C. U. Uyl‐de Groot, H. Lokhorst, 2011, Annals of Hematology.

Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study.

J. Baars, P. Sonneveld, E. Vellenga, 2002, Blood.

Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high‐dose methotrexate, and R‐DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study

M. Kersten, J. Baars, P. Lugtenburg, 2017, Hematological oncology.

Platelet Doubling After the First Azacitidine Cycle Is a Promising Predictor for Response in MDS, CMML and AML Patients in the Dutch Azacitidine Compassionate Patient Named Program

E. Vellenga, B. Biemond, G. Huls, 2011 .

The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients.

G. Peters, P. Sonneveld, W. Graveland, 2004, Blood.

Melphalan + Prednisone Versus Melphalan + Prednisone + Thalidomide in Induction Therapy for Multiple Myeloma in Elderly Patients: Final Analysis of the Dutch Cooperative Group HOVON 49 Study

P. Sonneveld, M. Kooi, H. Lokhorst, 2008 .

Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial

M. Kersten, H. Goldschmidt, P. Sonneveld, 2014, Haematologica.

Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program.

M. Kersten, P. Sonneveld, E. Vellenga, 2010, Clinical lymphoma, myeloma & leukemia.

HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly Diagnosed Multiple Myeloma (MM)

M. Kersten, D. Hose, H. Goldschmidt, 2010 .

Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial

M. Kersten, K. Nasserinejad, B. Hazenberg, 2019, Haematologica.

Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case‐matched study

S. Rosso, P. Sonneveld, M. Boccadoro, 2014, American journal of hematology.

Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison.

J. Baars, P. Sonneveld, B. van der Holt, 2009, Blood.

Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial.

P. Sonneveld, E. Vellenga, B. van der Holt, 2007, Haematologica.

Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials

P. Sonneveld, J. Miguel, M. Boccadoro, 2013, Haematologica.

prospective sibling donor versus no-donor comparison adult patients with acute lymphoblastic leukemia in first remission: a Myeloablative allogeneic versus autologous stem cell transplantation in

J. Baars, P. Sonneveld, G. Ossenkoppele, 2013 .

Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.

P. Sonneveld, R. van der Griend, H. Lokhorst, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials.

P. Fayers, P. Sonneveld, J. Mary, 2011, Blood.

Bortezomib Induction and Maintenance Treatment Improves Survival In Patients With Newly Diagnosed Multiple Myeloma: Extended Follow-Up Of The HOVON-65/GMMG-HD4 Trial

M. Kersten, D. Hose, H. Goldschmidt, 2013 .

A116 MP versus MPT in Elderly Myeloma Patients: The Final Outcome of the HOVON-49 Study

P. Sonneveld, H. Lokhorst, P. Wijermans, 2009 .

Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials

P. Sonneveld, B. Pégourié, M. Boccadoro, 2013, Haematologica.

Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

M. Kersten, D. Hose, H. Goldschmidt, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma.

P. Sonneveld, B. van der Holt, G. Ossenkoppele, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.